News Launch of ANDROMEDA 2.0 ANDROMEDA 2.0 will be launched on Feb 15th. Welcome to attend our release event in…Urban Fagerholm12 February 2024
News PROSILICO is happy to announce a strategic partnership with Phenaros Pharmaceuticals PROSILICO is happy to announce a strategic partnership with Phenaros Pharmaceuticals (https://www.phenaros.com/). Together, we will…Urban Fagerholm10 July 2023
News PROSILICO will attend and present at 2 conferences PROSILICO will attend and present at Biotech Hanse in Stockholm and RSC Anglo-Nordic Medicinal Chemistry…Urban Fagerholm13 June 2023
News PROSILICO attended IDDST in Tokyo and presented new results PROSILICO attended IDDST in Tokyo 8-10 May and gave an oral presentation of new ANDROMEDA…Urban Fagerholm22 May 2023
News ANDROMEDA by Prosilico outperforms laboratory methods In 49 study comparisons, ANDROMEDA by Prosilico outperformed laboratory methods in 74 % of cases…Urban Fagerholm21 March 2023
News PROSILICO participates in the planned SciLifeLab PULSE cofund postdoctoral programme PROSILICO participates in the planned SciLifeLab PULSE cofund postdoctoral programme SciLifeLab has the ambition to…Urban Fagerholm21 March 2023
News New article and ANDROMEDA milestone- Successful validation Validation of predicted conformal intervals for prediction of human clinical pharmacokinetics https://www.biorxiv.org/content/10.1101/2022.11.10.515917v1 Urban Fagerholm14 November 2022
News New article – Successful use of ANDROMEDA in cases where labs fail ANDROMEDA by Prosilico software successfully predicts human clinical pharmacokinetics of 70 drugs out of reach…Urban Fagerholm10 October 2022
News Steps in the right direction! FDA Modernization Act - The bill defines “nonclinical tests or studies ” as a test…Urban Fagerholm3 October 2022